Idera regains drug rights from Merck KGaA; Inhibitex stock jumps on expanded Phase II news;

 @FierceBiotech: It looks like bone. It feels like bone. For the most part, it acts like bone. And it came off an inkjet printer. Story | Follow@FierceBiotech

 @RyanMFierce: Idera ($IDRA) has rights to one of its TLR drugs, but no pharma partner in German Merck to help fund it. Release | Follow@RyanMFierce

 @MaureenFierce: Swiss pharmaceutical company wants Nebraska to return drug to be used in lethal injection. News | Follow @MaureenFierce

> Idera Pharmaceuticals ($IDRA) has regained rights to Phase II oncology drug IMO-2055 as part of an agreed-upon termination of its collaboration with Merck KGaA. Idera release

> The FDA has expanded approval of OraSure Technologies' hepatitis C test, which can diagnose the virus in 20 minutes. Report

> Russian's requirement that drug sponsors conduct local registration trials is interfering with the development of new medicines in that country. Article

> Inhibitex shares jumped on news that the FDA authorized the company to expand a Phase II trial of its hepatitis C drug INX-189. News

> The Canadian Institutes of Health Research says it will accept clinical trial proposals to test what's known as the Zamboni treatment, a procedure that was named after an Italian doctor who used stents inserted in veins in the head and neck to alleviate symptoms associated with multiple sclerosis. The procedure is not approved in Canada. More

> Fresh off the successful sale of their company Amira to Bristol-Myers Squibb ($BMY), founders Brad Bolzon and Peppi Prasit are trying their luck again with a new company called Inception. Story

> The biotech industry spent $2 million on lobbying in 3Q. Item

Pharma News

 @FiercePharma: Large-vial woes in Las Vegas: Surgeon sues Allergan over Botox vials that 'encourage reuse,' after Teva/propofol trials. News | Follow @FiercePharma> Surgeon sues Allergan over large Botox vials. Report

> Hospira's production woes widespread, analyst says. Story

> Surgeon sues Allergan over large Botox vials. News

Drug Delivery News

> FDA pins approval on new formulation of Ambien. Article

> Royal DSM injects delivery tech into scar-reduction alliance. Story

> Taris advances human testing of bladder pain treatment delivery device. More

Biomarkers News

> Researchers move closer to ADHD imaging biomarker. News

> Study tags sclerostin as biomarker of aortic valve. Article

> Lead biomarkers linked with stress. Report

> Researchers move closer to ADHD imaging biomarker. Story

> Researchers see microRNAs as prognostic markers for heart. Report

Medical Device News

> Boston Sci wins FDA nod for heart failure devices. Item

> QIAGEN to cut up to 10% of workforce. News

> AcuFocus rakes in $65M in funding. Story

And Finally... A yogurt a day keeps heart disease biomarkers at bay. Item

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.